Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zevra Therapeutics, Inc. (ZVRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, Zevra uses current reports on Form 8-K and other periodic filings to communicate material events, financial results, and governance changes related to its rare disease business.
Investors can review Form 8-K filings in which Zevra reports quarterly financial results and corporate updates, including revenue from its commercial products for Niemann-Pick disease type C and certain urea cycle disorders, operating expenses, and information about conference calls and webcasts. Other 8-K filings detail matters such as the resignation and transition of key officers, appointment of interim financial leadership, and board-level changes, along with summaries of related agreements and compensation terms.
These filings also document equity inducement awards granted under Zevra’s employment inducement award plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing transparency into stock option grants to new employees. Together with annual and quarterly reports (when available), the filings offer a structured view of Zevra’s financial condition, capital structure, and risk disclosures as it advances therapies like MIPLYFFA and OLPRUVA and develops candidates such as celiprolol.
On Stock Titan, SEC documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR help users see new Zevra filings as they appear, while specialized views of Forms 3, 4, and 5 make it easier to track insider transactions. For long-form reports such as 10-K and 10-Q, AI-generated highlights can help users quickly identify important sections on revenue drivers, research and development spending, and material risks related to Zevra’s rare disease portfolio.
Neil F. McFarlane, President and CEO of Zevra Therapeutics, Inc. (ZVRA), reported equity transactions on 10/10/2025. He received 50,000 restricted stock units (RSUs) that vested and settled under the company plan, bringing his direct holding to 241,516 shares. On the same date he sold 19,500 shares at a price of $10.8158, leaving him with 222,016 shares. The RSUs were part of an inducement award where 25% vested and settled on 10/10/2024 and another 25% on 10/10/2025, with the remaining 50% vesting in equal annual installments thereafter subject to continued employment; full vesting also occurs on a change of control or certain termination events. The sale was made pursuant to a 10b5-1(c) plan adopted 03/21/2025.
ZEVRA THERAPEUTICS, INC. (ZVRA) filed a Form 144 disclosing a proposed sale of 19,500 common shares by an insider through Morgan Stanley Smith Barney LLC on 10/10/2025. The filing lists an aggregate market value of $210,990 and shows 56,135,091 shares outstanding, implying the sale represents a small fraction of total shares.
The securities were acquired as Restricted Stock Units and the acquisition and planned sale date are both reported as 10/10/2025. No other sales in the prior three months are reported, and the filer affirms they are not in possession of undisclosed material adverse information.
Tamara A. Favorito, a director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 3,175 shares of the company's common stock on 09/12/2025 at a reported price of $7.7852 per share. After the transaction, Ms. Favorito beneficially owned 3,894 shares. The Form 4 was executed by Timothy J. Sangiovanni as attorney-in-fact and dated 09/16/2025.
Alvin Shih, a director of Zevra Therapeutics (ZVRA), purchased 20,000 shares of the company's common stock on 09/12/2025 at a weighted-average price of $7.89 per share. The Form 4 shows the transaction was reported as an acquisition and that the reporting person beneficially owns 20,000 shares following the purchase. The footnote states the $7.89 figure is a weighted average from multiple trades priced between $7.85 and $7.90 and that detailed allocation of trades is available on request. The filing was signed by an attorney-in-fact on behalf of Mr. Shih.
Zevra Therapeutics director John B. Bode acquired 5,000 shares of the company's common stock on 08/19/2025 at a reported price of $9.165 per share. After the purchase he beneficially owns 45,000 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/20/2025.
Zevra Therapeutics reported a net income of $74.7 million for the quarter ended June 30, 2025, driven largely by a $148.3 million gain on the sale of a transferable priority review voucher (PRV). Product revenue rose to $25.9 million for the quarter and $46.3 million year-to-date, led by MIPLYFFA sales of $21.5 million in the quarter.
The balance sheet strengthened with $47.7 million in cash and approximately $170.0 million in fair-value securities, bringing total assets to $256.3 million and stockholders' equity to $117.2 million. Material charges included a $58.7 million intangible-asset impairment related to OLPRUVA and an $11.7 million inventory write-down. Long-term debt was $60.7 million. The company disclosed ongoing litigation concerning the AZSTARYS license agreement.
Zevra Therapeutics announced it issued a press release on August 12, 2025 reporting financial results and corporate updates for the quarter ended June 30, 2025. The company scheduled a conference call and audio webcast for Tuesday, August 12, 2025 at 4:30 p.m. ET to discuss those results. The press release is furnished as Exhibit 99.1 to this Form 8-K and is explicitly furnished, not filed, so it is not incorporated by reference into Zevra's other securities filings. The Form 8-K does not include financial statements or tables within the filing itself.
Zevra Therapeutics, Inc. (ZVRA) – Form 4 filing dated 06/24/2025
The filing discloses an equity transaction by insider Rahsaan W. Thompson, who serves as Chief Legal & Compliance Officer and Secretary. On 06/21/2025, Thompson acquired 66,666 shares of common stock through the settlement of previously granted restricted stock units (RSUs). The transaction is coded “M,” indicating a conversion of a derivative security rather than an open-market purchase or sale.
Table II shows the RSU award underlying the transaction. The original grant totals 133,334 RSUs. According to the vesting schedule, one-third (66,666 units) vested and converted to common stock on 06/21/2025; the remaining two tranches will vest in equal annual installments, subject to continued service. Following the settlement, Thompson directly holds 66,666 shares of common stock and retains 133,334 unvested RSUs that may convert into an equal number of shares over the next two years.
No price is listed for the RSUs because the grant is equity-settled at no cash cost to the insider. There is no indication of open-market buying or selling, no mention of a 10b5-1 trading plan check-box selection, and no other classes of securities were involved. The filing is routine and does not provide information on company operations, earnings, or strategic initiatives.